Unknown

Dataset Information

0

Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.


ABSTRACT: The acquired drug resistance would influence the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer. The present study aimed to investigate the correlation of long non-coding RNA (lncRNA) H19 with cisplatin-resistance and clinical outcome in lung adenocarcinoma. In our study, the expression of H19 in cisplatin-resistant A549/DDP cells was unregulated. Knockdown of H19 restored the response of A549/DDP cells to cisplatin. H19-mediated chemosensitivity enhancement was associated with metastasis, induction of G0/G1 cell-cycle arrest, cell proliferation, and increased apoptosis. Furthermore, lncRNA H19 expression was significantly related to TNM stage and metastasis (P = 0.012). Overexpression of H19 was negatively correlated with cisplatin-based chemotherapy response in patients. Patients with high H19 expression exhibited a significantly shorter median progression-free survival (PFS) [4.7 months] than the low-expression patients (6.3months) [P = 0.002]. In summary, H19-mediated regulation of cisplatin resistance in human lung adenocarcinoma cells is demonstrated for the first time. H19 could potentially serve as a molecular marker to predict the clinical outcomes of lung adenocarcinoma patients.

SUBMITTER: Wang Q 

PROVIDER: S-EPMC5356823 | biostudies-other | 2017 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.

Wang Qi Q   Cheng Ningning N   Li Xuefei X   Pan Hui H   Li Chunyu C   Ren Shengxiang S   Su Chunxia C   Cai Weijing W   Zhao Chao C   Zhang Limin L   Zhou Caicun C  

Oncotarget 20170101 2


The acquired drug resistance would influence the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer. The present study aimed to investigate the correlation of long non-coding RNA (lncRNA) H19 with cisplatin-resistance and clinical outcome in lung adenocarcinoma. In our study, the expression of H19 in cisplatin-resistant A549/DDP cells was unregulated. Knockdown of H19 restored the response of A549/DDP cells to cisplatin. H19-mediated chemosensitivity enhancement was associate  ...[more]

Similar Datasets

| S-EPMC6308085 | biostudies-other
| S-EPMC4439130 | biostudies-literature
| S-EPMC5572850 | biostudies-literature
| S-EPMC5723956 | biostudies-literature
| S-EPMC8339970 | biostudies-literature
| S-EPMC5239489 | biostudies-literature
| S-EPMC7198444 | biostudies-literature
| S-EPMC7196199 | biostudies-literature
| S-EPMC6242979 | biostudies-literature
| S-EPMC7251775 | biostudies-literature